TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Maria is best known for her work on steroid 21-hydroxylase deficiency, the most common form of congenital adrenal hyperplasia (CAH). Most of her fellows and trainees in the late 1970s and early 1980s ...

developed a computed tomography (CT) -based radiological-clinical prediction model for evaluating the surgical difficulty of treatment using RPLA (Retroperitoneal Laparoscopic Adrenalectomy) based on ...

entitled “Automated Fluorescence Microscopy Method to Determine the Efficacy of Cancer and Hyperplasia Treatments”. Commercially known as “ACTA Technology” (Automated Cancer Treatment Assessment), ...

entitled "Automated Fluorescence Microscopy Method to Determine the Efficacy of Cancer and Hyperplasia Treatments". Commercially known as "ACTA Technology" (Automated Cancer Treatment Assessment ...

A pioneering new treatment promises to tackle a wider range of cancers, with fewer side-effects than conventional radiotherapy. It also takes less than a second. In a series of vast underground ...